Alpha Teknova, Inc.

NasdaqGM TKNO

Alpha Teknova, Inc. Receivables for the quarter ending September 30, 2024: USD 4.61 M

Alpha Teknova, Inc. Receivables is USD 4.61 M for the quarter ending September 30, 2024, a -10.76% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • Alpha Teknova, Inc. Receivables for the quarter ending September 30, 2023 was USD 5.16 M, a -18.97% change year over year.
  • Alpha Teknova, Inc. Receivables for the quarter ending September 30, 2022 was USD 6.37 M, a 10.77% change year over year.
  • Alpha Teknova, Inc. Receivables for the quarter ending September 30, 2021 was USD 5.75 M.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
Loading...
NasdaqGM: TKNO

Alpha Teknova, Inc.

CEO Mr. Stephen Gunstream
IPO Date June 25, 2021
Location United States
Headquarters 2290 Bert Drive
Employees 210
Sector Health Care
Industries
Description

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

Similar companies

PROC

Procaps Group S.A.

USD 1.76

7.98%

LFCR

Lifecore Biomedical, Inc.

USD 6.43

1.10%

RGC

Regencell Bioscience Holdings Limited

USD 4.86

-4.71%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

COLL

Collegium Pharmaceutical, Inc.

USD 33.18

-1.80%

ORGO

Organogenesis Holdings Inc.

USD 2.89

-3.67%

StockViz Staff

January 15, 2025

Any question? Send us an email